|
Market Closed -
Japan Exchange
06:30:00 11/03/2026 GMT
|
5-day change
|
1st Jan Change
|
|
10,880.00 JPY
|
+6.77%
|
 |
+7.88%
|
+22.62%
|
|
03-04 |
Irlab Working to Secure Funding for Phase 3 Study of Mesdopetam - fc
|
FW
| |
02-26 |
Irlab Receives $3 Million Milestone Payment Following Dosing in Phase 1b Study
|
FW
| |
02-14 |
Otsuka Holdings Co., Ltd., 2025 Earnings Call, Feb 13, 2026
| | |
02-13 |
Otsuka Holdings Co., Ltd. Announces Dividend for the Fiscal Year Ended December 31, 2025, Payable on March 30, 2026
|
CI
| |
02-13 |
Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Second Quarter (Year to Date) and for the Year Ending December 31, 2026
|
CI
| |
02-13 |
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal 2026 and Year Ending December 31, 2026
|
CI
| |
02-13 |
Otsuka Holdings Co., Ltd. authorizes a Buyback Plan.
|
CI
| |
02-13 |
Otsuka Holdings Co., Ltd. announces an Equity Buyback for 7,000,000 shares, representing 1.33% for ¥50,000 million.
|
CI
| |
02-13 |
Japan Stocks End Week in Red As BOJ Hawk Flags Near-Term Rate Rise
|
MT
| |
02-13 |
Otsuka Holdings Co Ltd to buy back up to 1.33% of own shares worth 50 billion yen
|
RE
| |
02-13 |
Otsuka Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
02-13 |
Otsuka's Profit Climbs 20% in 2025
|
MT
| |
02-04 |
Biodexa announces exclusive license of Otsuka's OPB-171775, a potent phase 1 ready molecular glue for GIST
|
RE
| |
02-04 |
HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025
|
CI
| |
02-02 |
Otsuka Corporation Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026
|
CI
| |
02-02 |
Otsuka Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026
|
CI
| |
01-27 |
Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program
|
RE
| |
01-22 |
Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says
|
MT
| |
01-14 |
Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group
|
AQ
| |
01-12 |
Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026
|
CI
| |
12-28 |
Final dividend
|
FA
| |
11-26 |
Otsuka Wins U.S. FDA Accelerated Approval for VOYXACT
|
MT
| |
11-25 |
Otsuka Holdings Co receives FDA accelerated approval for Voyxact for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression
|
RE
| |
11-25 |
Fda approves use of Voyxact to reduce proteinuria in primary immunoglobulin
|
RE
| |
11-25 |
US FDA approves Otsuka's drug for a type of kidney disease
|
RE
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
